On March 27, 2026, BTIG maintained its Buy rating on Humacyte but cut its price target to $3 from $6 after the company reported fourth-quarter and full-year 2025 results earlier the same day.

The data showed that roughly 65% of the cells in the oxygenated devices remained viable compared to roughly 20% in control devices.

Humacyte, a leader in bioengineered vessel technologies, has announced strong fourth quarter and full year 2025 results, ...

Researchers have designed a bioresorbable implant that regenerates esophageal tissue after cancer surgery. The device aims to ...

Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a ...

Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - - Purchase commitment received for a minimum of $1.475 million for a clinica ...

For all the recent messaging about “body positivity”, the search for a balding “fix” has become “increasingly desperate – and ...

For individuals living with chronic or non-healing wounds, finding effective treatment close to home can be life changing. At ...

Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand corporate ...

First-Of-Its-Kind Non-Human Wound Product Combines Mānuka Honey, Collagen Derivative, And Hydroxyapatite To Redefine ...

Microplastics are all over the environment and even inside human bodies. Researchers have found a type of bioengineered algae ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company ...